<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767531</url>
  </required_header>
  <id_info>
    <org_study_id>012013-042</org_study_id>
    <nct_id>NCT02767531</nct_id>
  </id_info>
  <brief_title>Orlistat for the Treatment of Type I Hyperlipoproteinemia</brief_title>
  <acronym>T1HLP</acronym>
  <official_title>Orlistat for the Treatment of Type I Hyperlipoproteinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Type I Hyperlipoproteinemia (T1HLP) have a rare form of hypertriglyceridemia&#xD;
      marked by significant chylomicronemia and recurrent episodes of acute pancreatitis. T1HLP is&#xD;
      caused by a deficiency of lipoprotein lipase or one of its cofactors. Many patients are a&#xD;
      challenge to treat, as the only effective therapy available is an extremely low fat diet.&#xD;
      This diet is exceedingly difficult to follow, and despite adherence, many patients still have&#xD;
      chylomicronemia and develop acute pancreatitis.&#xD;
&#xD;
      Specific Aim: To determine the efficacy of a gastric and pancreatic lipase inhibitor,&#xD;
      Orlistat, in reducing serum triglyceride levels in patients with T1HLP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type I hyperlipoproteinemia is a rare, autosomal recessive metabolic disorder characterized&#xD;
      by extreme hypertriglyceridemia due to a deficiency in lipoprotein lipase or related&#xD;
      proteins. Treatment of these patients is challenging as triglyceride-lowering medications are&#xD;
      ineffective. A low fat diet is helpful, however, despite good dietary compliance, some&#xD;
      patients continue to have severe hypertriglyceridemia and recurrent pancreatitis which can be&#xD;
      life threatening. Therefore, Investigator wish to investigate whether inducing dietary fat&#xD;
      malabsorption or inhibiting chylomicron formation will cause further lowering of serum&#xD;
      triglycerides (TG) beyond the effect of limiting dietary fat intake.&#xD;
&#xD;
      Investigator will study the efficacy and safety of an inhibitor of intestinal lipase&#xD;
      (Orlistat) for reducing serum triglyceride levels in patients with Type I&#xD;
      hyperlipoproteinemia. Investigator plan to enroll 20 patients with Type I&#xD;
      hyperlipoproteinemia in a randomized, double-blind, placebo-controlled, cross-over trial.&#xD;
      During the last week of each study period, fasting blood samples will be drawn for three&#xD;
      consecutive days for serum lipids and chemistry panel. The primary endpoint will be serum&#xD;
      triglycerides; the secondary endpoint variables will be fasting and postprandial serum&#xD;
      chylomicron-TG levels, postprandial serum TG levels during a meal tolerance test and retinyl&#xD;
      palmitate levels during a meal tolerance test. Repeated measures analysis of variance will be&#xD;
      used for statistical comparisons.&#xD;
&#xD;
      These results may help in designing novel therapeutic approaches for patients with Type 1&#xD;
      hyperlipoproteinemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting Serum Triglycerides</measure>
    <time_frame>3 days</time_frame>
    <description>Fasting blood samples were collected on three consequetive days at the end of each three month period. Mean values of the three days were calculated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Hyperlipoproteinemia Type I</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Orlistat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 mg of Orlistat will be given 3 times to patients weighing greater than 50 kg and patients weighing less than 40 kg will be given 60 mg of Orlistat 3 times a day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Off drug</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard therapy will be given for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat</intervention_name>
    <description>Orlistat is a gastric and pancreatic lipase inhibitor that is approved by the FDA for weight loss. It is available over-the-counter as 60 mg tablets under the trade name Alli, and available by prescription as 120 mg capsules under the trade name Xenical.</description>
    <arm_group_label>Orlistat</arm_group_label>
    <other_name>Alli</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type I hyperlipoproteinemia&#xD;
&#xD;
          2. Fasting serum triglyceride levels of greater than 1000 mg/dL&#xD;
&#xD;
          3. Age &gt; 8 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Secondary hypertriglyceridemias due to diabetes, renal disease, hypothyroidism,&#xD;
             alcoholism and drug therapy such as estrogens and estrogen analogues, steroids,&#xD;
             HIVprotease inhibitors, retinoic acid derivatives and interferons&#xD;
&#xD;
          2. Pregnant or lactating women&#xD;
&#xD;
          3. Significant liver disease (elevated transaminases &gt; 2 times upper limit of normal)&#xD;
             Alcohol abuse (&gt; 7 drinks or 84 g per week for women and &gt; 14 drinks or 168 g per week&#xD;
             for men)&#xD;
&#xD;
          4. Severe anemia (hematocrit &lt; 24%)&#xD;
&#xD;
          5. Drug use (cocaine, marijuana, LSD, etc.)&#xD;
&#xD;
          6. Major surgery in the past three months&#xD;
&#xD;
          7. Congestive heart failure&#xD;
&#xD;
          8. Serum creatinine greater than 2.5 mg/dL&#xD;
&#xD;
          9. Cancer within the past five years&#xD;
&#xD;
         10. Gastrointestinal surgery in the past&#xD;
&#xD;
         11. Current therapy with anti-coagulants, digoxin, and anti-arrhythmics&#xD;
&#xD;
         12. Current therapy with cyclosporine&#xD;
&#xD;
         13. Chronic malabsorption syndromes&#xD;
&#xD;
         14. Cholestasis&#xD;
&#xD;
         15. Acute illnesses such as acute pancreatitis in the last 8 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhimanyu Garg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center 5323 Harry Hines Blvd</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8537</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 2, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <results_first_submitted>November 19, 2018</results_first_submitted>
  <results_first_submitted_qc>January 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2019</results_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Abhimanyu Garg</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type I</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT02767531/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A randomized,open-label, crossover trial with four periods and two sequences (&quot;orlistat&quot; and &quot;off&quot; for 3 months each) was conducted.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Orlistat Then Off Therapy</title>
          <description>Randomized to Orlistat for first 3 months, then cross over to no therapy for 3 months, followed by repeat sequence of Orlistat for additional 3 months, and no therapy for next 3 months</description>
        </group>
        <group group_id="P2">
          <title>Off Orlistat Then Orlistat</title>
          <description>Randomized to no therapy for first 3 months and then cross over to Orlistat for 3 months and then repeat sequence of no therapy for additional 3 months and then Orlistat for next 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1">Orlistat therapy</participants>
                <participants group_id="P2" count="1">Off Orlistat</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1">Off Orlistat</participants>
                <participants group_id="P2" count="1">Orlistat Therapy</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1">Orlistat Therapy</participants>
                <participants group_id="P2" count="1">Off Orlistat</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1">Off Orlistat</participants>
                <participants group_id="P2" count="1">Orlistat Therapy</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Baseline Features of Patients Enrolled</title>
          <description>120 mg of Orlistat will be given 3 times to patients weighing greater than 50 kg and patients weighing less than 40 kg will be given 60 mg of Orlistat 3 times a day for 3 months.&#xD;
The patients were randomized to receive 3 months of orlistat or no therapy (off), then crossed over to the other arm, and this sequence was then repeated for an additional 6 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglyceride</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1674" lower_limit="1611" upper_limit="1737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fasting Serum Triglycerides</title>
        <description>Fasting blood samples were collected on three consequetive days at the end of each three month period. Mean values of the three days were calculated.</description>
        <time_frame>3 days</time_frame>
        <population>The patients were randomized to receive 3 months of orlistat or no therapy (off), then crossed over to the other arm, and this sequence was then repeated. Because only 2 patients participated, the results are provided per sequence and not per intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat and Then Off Therapy</title>
            <description>Randomized to Orlistat for first 3 months, then cross over to no therapy for 3 months, followed by repeat sequence of Orlistat for additional 3 months, and no therapy for next 3 months&#xD;
120 mg of Orlistat will be given 3 times to patients weighing greater than 50 kg and patients weighing less than 40 kg will be given 60 mg of Orlistat 3 times a day for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Off Therapy and Then Orlistat</title>
            <description>Randomized to no therapy for first 3 months and then cross over to Orlistat for 3 months and then repeat sequence of no therapy for additional 3 months and then Orlistat for next 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Serum Triglycerides</title>
          <description>Fasting blood samples were collected on three consequetive days at the end of each three month period. Mean values of the three days were calculated.</description>
          <population>The patients were randomized to receive 3 months of orlistat or no therapy (off), then crossed over to the other arm, and this sequence was then repeated. Because only 2 patients participated, the results are provided per sequence and not per intervention.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="705" lower_limit="656" upper_limit="730"/>
                    <measurement group_id="O2" value="1827" lower_limit="1266" upper_limit="2320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1511" lower_limit="1226" upper_limit="1750"/>
                    <measurement group_id="O2" value="1007" lower_limit="964" upper_limit="1040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="758" lower_limit="617" upper_limit="876"/>
                    <measurement group_id="O2" value="3121" lower_limit="2780" upper_limit="3490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1614" lower_limit="1540" upper_limit="1680"/>
                    <measurement group_id="O2" value="1181" lower_limit="1122" upper_limit="1248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Orlistat</title>
          <description>Each of the two patients, were randomized to receive Orlistat for 3 months in two periods.&#xD;
Patient 1 took Orlistat 60 mg with the first and second meal and 120 mg with the third meal, whereas Patient 2 took 60 mg of Orlistat 3 times daily with meals.</description>
        </group>
        <group group_id="E2">
          <title>Off Therapy</title>
          <description>Each of the two patients, were randomized to &quot;Off therapy&quot; for 3 months in two periods.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating</sub_title>
                <description>Patient1 had a mild increase in passage of gas and bloating, and patient 2 had constipation with mild stool leakage.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Abhimanyu Garg, MD</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>2146482895</phone>
      <email>abhimanyu.garg@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

